跳到正文
原文
Nature Medicine· Li Du·· 9 天前AI 评分45

中国基因编辑疗法临床试验中出现死亡事件揭示监管漏洞

Lessons from recent investigator-initiated trials of gene-editing therapies in China

AI 导读

多项由中国研究者发起的细胞和基因编辑疗法临床试验中出现死亡事件,反映出当前监管和监督存在不足。建议增加独立外部审查以加强高风险疗法的临床监督。

正文

Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04768-x

Several deaths during trials of experimental cell and gene therapies in China appear to reveal gaps in governance and oversight. A new layer of independent external review is needed for clinical supervision of high-risk therapies.

来源:Nature Medicine · nature.com